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Cystic ﬁbrosis (CF) is a generalized disorder of exocrine epithelia
that is caused by mutations in the CFTR gene (OMIM 219700) [1]. The
single 3-bp deletion F508del is present on at least one allele in more
than 90% of CF patients [2], thus making it the most common disease-
causing lesion in autosomal recessive traits of Caucasian populations.
Phenylalanine 508 resides on the surface of the ﬁrst nucleotide
binding domain (NBD1) of CFTR [3]. Deletion of F508 exerts only
minor local effects on NBD1 structure around position 508 [3,4], but
it precludes the proper assembly between the cytoplasmic and
membrane-integrated domains of CFTR [5]. In vitro most of the
newly synthesized F508del CFTR fails to adopt a wild-type fold in the
ER [3] and is targeted for ER-associated degradation [6]. Chaperone-
assisted modulation of the folding of the nascent protein [7] or
biosynthesis at temperatures below 30 °C [8] can rescue F508del
CFTR. However, any F508del CFTR protein that reaches the cell
surface remains thermally unstable, capable of only partial chloride
channel activity [9], and is rapidly endocytosed and ﬁnally deliveredto the lysosome for degradation [10]. In summary, F508del CFTR has
been classiﬁed as a trafﬁcking- and processing-deﬁcient mutation
[11].
Concurrent with this classiﬁcation inferred from cellular models,
only mislocalized F508del CFTR protein was immunodetectable in
F508del homozygotes' sweat glands [12,13]. Literature reports on the
F508del CFTR phenotype in human airways [13–17] and human
intestine [13,18,19], however, are inconsistent. Our group has
described the presence of the mature complex-glycosylated F508del
CFTR on immunoblots from intestinal tissue [13] and residual F508del
CFTR-mediated chloride conductance in some F508del homozygous
intestinal epithelia [18]. These ﬁndings were challenged by a
subsequent study which applied a new set of anti-CFTR antibodies
[19]. No F508del CFTRmature protein or function could be detected in
rectal mucosa [19].
Considering the conﬂicting outcome of our initial and the more
recent study we decided to re-investigate the patients' F508del CFTR
phenotype. Clariﬁcation of the molecular pathology of F508del CFTR in
human tissue is not only of academic interest. In the light of the
discovery of synthetic smallmolecules [20] that either reinforce residual
CFTR activity (‘potentiators’) or normalize processing and trafﬁcking of
CFTR to the apical membrane (‘correctors’) it is critically important to
know whether or not some properly processed F508del CFTR protein
with residual activity is present in the affected individuals.
In the present study the molecular pathology of F508del CFTR was
characterized in freshly excised rectal mucosa by bioelectric measure-
ment of the basic defect followed by CFTR protein analysis. The ex vivo
analysis of rectal suction biopsies revealed that the majority of
investigated F508del homozygous individuals expressed low amounts
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CFTR-mediated chloride secretory activity in the rectal mucosa.
2. Materials and methods
2.1. Subjects and volunteers
Twenty F508del homozygous (Table S1), one R553X homozygous
and one CFTRdele2,3 (21 kb) homozygous CF subjects were examined.
Their clinical status was determined by weight predicted for height
(wfh) % (representative for the nutritional status) and FEVPERC
(representative for the pulmonary status) [18]. Biopsies of non-CF
healthy volunteers (n=30, age of 19–43 years) were characterized by
ICM together with biochemical CFTR analysis. The study (no. 2771) was
approved by the Ethics Committee of Hanover Medical School. All
participants of the study and/or their parental guides provided written
informed consent.
2.2. Rectal suction biopsies and lung epithelium specimens
Two to four rectal biopsies were collected with a suction biopsy
device (Model SBT-100, Trewavis Surgical, Bayswater, Australia) from
each subject (see the typical histology of a non-CF biopsy in Fig. S1).
After intestinal current measurement (ICM) the specimens were
immediately processed for immunohistochemistry or biochemical
analysis. Histology was assessed in hematoxylin-eosin stained 4-μm
sections of parafﬁn-embedded biopsies that had been ﬁxed with
formaldehyde.
Native CF lung epithelium specimens were obtained from freshly
explanted CF lungs on the occasion of lung transplantation and snap
frozen in liquid nitrogen. Non-CF lung epithelium specimens were
analyzed from parts of non-CF lung explants that underwent structural
control by histology, demonstrating regular airway epithelium and
submucosal glands.
2.3. ICM
The electrogenic transport of ions across the intestinal epithelium
was measured as short circuit current (Isc) by ICM following our
previouslypublishedprotocol andevaluation algorithm[18,21]. Biopsies
of the rectal mucosa were mounted into an adapted micro-Ussing
chamber with an aperture of 1.13 mm2. Basal transepithelial resistance
of the tissue was determined by measuring voltage response to pulse
currents of 1 μA, and basal ISc was calculated from the basal and the
open-circuit transepithelial resistance (Table S2).
2.4. Antibodies
The following anti-CFTR Abs were used: polyclonal R453 [22] and
R16 against the N-terminus (aa 1–14, R16/34) and C-terminus (aa
1466–1480, R16/33), polyclonal R40 [19] against C-terminus (aa 1465–
1488), polyclonal PAC865 [13] against NBD2 (aa 1377–1409), mAb 596
[19] against NBD2 (aa 1204–1211), mAb 570 [19] against R-domain (aa
731–742), mAb L12B4 [12] against NBD1 (aa 386–412, Chemicon) and
mAb M3A7 [12] against NBD2 (aa 1370–1380, Chemicon). All antibody
lots were veriﬁed to recognize the B- and C-bands of CFTR in T84 cells.
For more information about the characteristics of the polyclonal
anti-CFTR antibodies the reader is referred to Table S3.
2.5. CFTR immunoblot analysis
The freshly excised biopsy specimens (n=2–4) were homoge-
nized in the presence of 10 mM iodoacetamide, 20 mM PMSF,
20 μg/ml pepstatin and antipain, 100 μg/ml leupeptin and aproto-
nin and 500 μg/ml soybean trypsin-inhibitor in Tris buffer (20 mM
Tris/HCl, 150 mM NaCl, pH 8). The lysis started by incubation with0.03% SDS for 30 min, followed by 1% (v/v) Triton X-100 and 0.5%
(w/v) sodium deoxycholate for 30 min. After centrifugation
(16,000×g, 4 °C, 20 min) the supernatant was incubated with
protein A-sepharose (PAS, GE Healthcare) or with the speciﬁc
pre-immune serum and PAS for 60 min. Immunoprecipitation (IP)
was carried out overnight with the polyclonal antibodies R40
(1:50) and R453/R16 (1:50) or R40 (1:50) plus R16/33 (1:67) and
R16/34 (1:40) in the presence of PAS (GE Healthcare) and protein
G-agarose (Santa Cruz). All pellets were washed several times with
(1) PBS with 0.5% (v/v) Triton X-100 and 0.05% (w/v) sodium
deoxycholate and (2) 125 mM Tris, 500 mM NaCl, 10 mM EDTA,
0.5% (v/v) Triton X-100, pH 8. CFTR-immunoreactive bands were
detected on 5% SDS–PAGE separated PVDF-membranes with mAbs
570 and 596 (1:500) in 0.2% I-Block (Tropix, Applied Biosystems) in
0.05% Tween-TBS (T-TBS) and pre-adsorbed anti-mouse-IgG-HRP
from donkey (1:300000, abcam) in 0.2% I-Block in T-TBS incubating
with ECL Advance (GE Healthcare) for 20 s. Exposure times were
chosen between 20 s and up to 20 min as time series for each
sample. The non-CF samples were exposed between 5 s and up to
5 min. As markers for calibration of the CFTR B- and C-bands in
rectal biopsies the B- and C-bands of T84 immunoprecipitates
separated on the same gel and the protein marker Precision Plus
Protein Standards All Blue (10–250 kDa, BIO-RAD) were used. The
amount of protein (experimental error±11%) was determined by
the Bradford assay [23] and the CFTR-immunoreactive signal was
quantiﬁed by densitometry of a time series of Hyperﬁlms ECL (GE
Healthcare) exposed to ECL Advance-covered immunoblot. For
digestion with endo-β-N- acetylglucosaminidase H (Endo H, Roche)
immunoprecipitated proteins were eluted in 0.5% SDS and 1%
mercaptoethanol at 37 °C for 1 h. The treatment with Endo H was
performed as described by Naim et al. [24].
2.6. Metabolic labelling
After ICM two rectal biopsies were placed on a stainless steel grid
and labelled biosynthetically with 15.4 MBq [35 S]cysteine and
18.5 MBq [35 S]methionine (GE Healthcare) in methionine and
cysteine-deﬁcient D-MEM medium (Invitrogen) supplemented with
streptomycin and penicillin (Invitrogen) following the protocol that
was initially established for the analysis of lactate-phlorizin hydrolase
[24,25] and more recently adapted for the analysis of CFTR [22]. The
biopsies were incubated for 15 h at 37 °C, but the controls of non-CF in
lanes a and c in Fig. 7 only for 5 h and in lane b for 16 h [22]. Lysis, IP
and SDS–PAGE were performed as described in the immunoblot
section. The antibodies used for the IP are shown in the heading of
Figs. 7 and 8. The vacuum-dried gels were exposed to Biomax MR1
ﬁlms (Kodak). For calibration of the CFTR 35 S-labelled signals the
labelled signals of the control protein sucrase-isomaltase (SI) [22] and
the prestained molecular weight marker (mol. wt., 26.6–180 kDa,
Sigma) were used. However, the molecular weights of the 7 major
bands varied between lots. Themarker protein alpha 2-macroglobulin
from human plasma as highest standard band varied between 167.7
and 187.3 kDa.
3. Results
3.1. Immunodetection of CFTR in rectal biopsies: setup of the protocol
CFTR protein analysis in human specimens is critically dependent
on a sufﬁcient speciﬁcity and sensitivity of the applied immuno-
chemical tools. This work employed a panel of own polyclonal peptide
anti-CFTR antibodies (Fig. 1, Table S3) and new generation high
afﬁnity monoclonal anti-CFTR antibodies the latter of which had been
developed in the course of the recent studies by our peers on F508del
homozygotes [19].
Fig. 1. Immunodetection of CFTR in lysates of non-CF rectal suction biopsies by
immunoprecipitation (IP) and subsequent immunoblot. (A) After lysis of four fresh
biopsies IPs were carried out with the pre-immune serum (PPI) R40 and R453 (lane b)
or the polyclonal anti-CFTR Abs R40 and R453 (lanes a and c). CFTR was detected on the
immunoblot of PAGE-separated IPs with the anti-CFTR mAbs 570 and 596 (lanes b and
c) and the secondary Ab anti-mouse-IgG-HRP (lanes a–c). In lane c a strong complex-
glycosylated C-band and a very weak mannose-rich B-band of CFTR was detectable, but
not in lane a (secondary Ab) and in lane b (PPI and secondary Ab). (B) Treatment with
Endo H (lanes b and d) deglycosylated the mannose-rich, but not the complex-
glycosylated CFTR isoform in biopsies (lane a) and T84 cells (lane c). IPs were carried
out with the polyconal anti-CFTR Abs R40, R16/33 and R16/34. (C) IPs of lysed biopsies
of non-CF controls with different mixtures of polyclonal anti-CFTR Abs (lanes a, b: R40
and R453; lanes c, d: R40, R16/R33 and R16/R34) resulted in comparable normalized
CFTR-immunoreactive signals of band B and band C on blots. Each lane in panel C
represents a separate immunoblot.
Fig. 2. Immunodetection of CFTR in lung and distal intestine. Lysates of T84 cells
(15.6 mg protein), non-CF rectal biopsies (1.28 mg), non-CF (6.6 mg) and F508del
homozygous CF (6.4. mg) lung epithelium specimens were immunoprecipitated with
polyclonal anti-CFTR Abs. CFTR was detected on the immunoblot of PAGE-separated IPs
with the anti-CFTR mAbs 570 and 596. Please note the differential glycosylation
patterns of band C CFTR in lung and rectal intestine and the about ﬁvefold lower
normalized CFTR-immunoreactive signal in the lung sample than in the rectum
sample. The F508del CFTR band B signal was there, but barely visible.
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lysate was immunoprecipitated with anti-CFTR Abs, and CFTR then
visualized by anti-CFTR mAb on the immunoblot of the PAGE-
separated IP. A strong band C of the mature complex-glycosylated
CFTR and a faint band B of the immature core-glycosylated CFTR were
regularly detected in rectal biopsies collected from non-CF control
subjects (Fig. 1A, lane c; Fig. 1C). Neither the pre-immune sera nor the
secondary Ab produced any non-speciﬁc by-bands in the sensitive
mol. wt. range for CFTR detection of above 100 kDa (Fig. 1A, lanes a
and b). The various polyclonal anti-CFTR Abs which were used for
immunoprecipitation in the course of the study resulted in compa-
rable patterns of immunoreactive CFTR signals on blots (Fig. 1C, lanes
a, b vs. c, d). Incubation with EndoH led to the expected shift of the
faint band B to the non-glycosylated band A (Fig. 1B) which veriﬁedthat band B represented the mannose-rich ER isoform of CFTR.
Immunodetection of CFTR was possible in fresh and snap-frozen
biopsies; however, the same amount of protein lysate derived from
frozen and fresh biopsies revealed a fainter CFTR signal in the former
(data not shown). By strictly adhering to the upper limit of allotted
biopsies per subject approved by the ethics committee, F508del CFTR
protein analysis was reliably feasible in our hands with fresh, but not
with frozen samples.
Fig. 2 compares the CFTR-immunoreactive signals in samples from
lungs and distal intestine. The mature glycoform C differed in its
glycosylation pattern between the two tissues and the normalized CFTR
signal was about ﬁvefold lower in non-CF lung specimens (n=7) than
in non-CF rectal biopsies (n=30). Mutant CFTR-immunoreactive
signals from lung explants were either not detected in immunoblots
(n=2) or marginally above the sensitivity threshold of detection
(n=5). No complex-glycosylated F508del CFTR was detectable.
3.2. Study population
Table S1 compiles the clinical status of the 20 F508del homozygous
subjects (median age: 13.8 years; range: 7.3–36.8 years) at the day of
investigation when they provided rectal biopsies for the characteriza-
tion of theirmutant CFTRphenotype. The recruited subjectsweremildly
or moderately affected by CF disease, only 5 of the 20 subjects were
more compromised in their lung function than their average CF peer of
the same age and gender (Table S1). The eldest female (no. 3) andmale
participants (no. 5)were themostmildly affected F508del homozygous
subjects at the CF clinic Hannover who had never been hospitalized
because of CF-related symptoms.
3.2.1. ICM of F508del homozygous rectal mucosa
Of the 20 F508del CFTR homozygous subjects who provided rectal
suction biopsies for CFTR protein analyses, the ICM revealed low anion
secretory activity in the colonic epithelium of 18 individuals.
Carbachol typically evoked a small residual anion secretory response
of 0.1–3.8 μA/cm2 in the F508del homozygous rectal mucosa, whereas
samples of non-CF individuals exhibited mean responses of 30 μA/
cm2 (Fig. 3, Table S2). The ICM tracing of the biopsy taken from CF
subject 9 with close-to-normal response to cAMP/forskolin was a
Fig. 3. ICM tracings of rectal suction biopsies. An upward response denotes net chloride and bicarbonate secretion, a downward response denotes net potassium secretion unmasked
in the absence of chloride secretion (observed in CF condition only) [21]. A chloride secretion in the presence of DIDS is attributed to CFTR. The ICM tracing of the non-CF subject
(tracing A) shows the characteristic pattern of a healthy subject with large and nearly identical chloride secretory responses to carbachol and histamine of more than 20 μA/cm2
together with a response to cAMP in the normal range. No net chloride secretory responses are seen in the tracing B of a CF subject who is homozygous for a CFTR null allele, the large
out-of-frame deletion CFTRdele2,3 (21 kb). The two tracings of F508del homozygous CF patients show either no net chloride secretion (tracing D) or residual chloride secretion that
is attributable to CFTR because of the secretory response to DIDS/histamine (tracing C). In tracing D after the response of carbachol a current drift was measured without any
response to 8-Bromo-cAMP/Forskolin.
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homozygotes revealed responses in the typical CF range (Table S2)
[21,26,27]. Both DIDS-insensitive (i.e., F508del CFTR) and DIDS-
sensitive alternative anion conductances [21] contributed to variable
extent to the anion secretory activity of F508del homozygous rectal
mucosa (Table S2), whereas in non-CF tissue virtually all anion
secretion was attributed to CFTR as indicated by matching responses
to carbachol and histamine (Fig. 3A). The two homozygotes for the
nonsense mutation R553X or the large out-of-frame deletion
CFTRdele2,3(21 kb) in the CFTR gene were expected to express no
functional CFTR. These CF disease controls indeed showed full-blown
CFTR loss-of-function phenotypes in the ICM with no net anion
secretory responses to carbachol, cAMP and histamine (Fig. 3B).
The ICM protocol adhered to the standardized procedure [21,28]
established by Veeze et al. [29,30]. Data of this study could thus be
compared with all previous recordings with the same ICM setup,
registration mode and protocol at the CF centres in Rotterdam and
Hannover on 269 non-CF and 301 CF subjects [27]. All F508del
homozygotes investigated in this study but subject 9 had a cumulative
value of the responses (ΔIsc carbachol+ΔIsc cAMP/forskolin+ΔIsc histamine;
median: 5.5, range: −2.0 to 13.2, outlier: 46.8 μA/cm²) within the
typical CF range usually far below the cut off at 34 μA/cm² that is the
best diagnostic ICM parameter to differentiate CF from non-CF [27].3.3. CFTR protein analysis of F508del homozygous rectal mucosa
CFTR protein analysis of rectal biopsies was performed immediately
after ICM by the two complementary techniques of either immunoblot
or metabolic labelling that identify steady state levels or newly
synthesized protein, respectively. Since rectal biopsies were processed
individually by subject, the work-up steps strictly adhered to the
standardized protocols described above in order to minimize any
technical in-between sample variation of the detected CFTR signals.
Biopsies collected from non-CF subjects showed a strong complex-
glycosylated C-band and a weak mannose-rich B-band of CFTR in the
immunoblot (Fig. 5, lane a). F508del CFTR-immunoreactive signals of
rectal biopsies of F508del homozygous subjects were in the range of
the B-band of non-CF controls (Fig. 6). The F508del CFTR B and C
isoforms were detected in highly variable absolute and relative
amounts in the rectal mucosa of the individual CF donors (Fig. 5, lanes
b–f; Fig. 6, Table 1, Fig. S2). The complex-glycosylated isoform was
visible in ten and the mannose-rich isoform in all thirteen F508del
homozygous specimens analyzed by immunoblot. The normalized
densitometric signal of the F508del CFTR glycoform C varied between
0% and 14% (median: 3%) of the signal of wild-type band C (Fig. 6,
Table 1), the ratio F508del C/F508del B varied between 0 and 40
(median 0.8) (Table 1). The expression levels of B-, C-isoform or total
Fig. 4. ICM tracing and CFTR immunoblot of the F508del homozygous CF subject 9. (A)
The ICM tracing shows a high response to cAMP/forskolin being atypical for F508del
homozygous CF. Although the CF-typical signature of a reverse response to carbachol
was observed, the secretory response to cAMPwas larger than the average response of a
non-CF rectal mucosa. The CF-typical residual response to histamine indicates that
F508del CFTR contributes to chloride secretion. (B) The immunoblot shows a strong B-
band of core-glycosylated and a weaker, but clearly visible C-band of complex-
glycosylated F508del CFTR. The mature C glycoform is known to form the ion channel in
the apical epithelial membrane.
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Fig. 6. Contents of CFTR B-band and C-band in immunoblots of SDS–PAGE separated
anti-CFTR IPs of rectal mucosal biopsies of F508del homozygous subjects (con, non-CF
control). The normalized density indicates the immunoreactive CFTR signal on an X-ray
ﬁlm that had been exposed for 1 min to the immunoblot covered with ECL Advance.
B- and C-F508del CFTR glycoforms were detected in highly variable amounts and C/B
ratios (see Table 1).
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insensitive chloride secretory response in ICM (Table S2). In other
words, the electrophysiological signature of an F508del homozygous
biopsy in the ICM was not associated with its proﬁle of F508del CFTR
protein isoforms.
Metabolic labelling of rectal biopsies with [35 S]cysteine and [35 S]
methionine and subsequent IP with a cocktail of anti-CFTR antibodies
led to the appearance of bands that were consistent with the expected
shape and size of core- and complex-glycosylated CFTR isoforms
(Fig. 7). Based on established protocols for the metabolic labelling of
intestinal biopsies [24,25], we had adapted and optimized the
procedure for the analysis of CFTR [22]. Thanks to this previousFig. 5. Detection of CFTR or F508del CFTR in rectal mucosa of non-CF and F508del
homozygous CF subjects. Four freshly excised rectal suction biopsies were examined in
their responses to secretagogues by ICM and immediately thereafter for their CFTR-
immunoreactive signals by immunoblot of IPs following a standardized protocol for
sample processing and analysis. Each lane represents a separate immunoblot. In 4 of 5
F508del homozygous CF samples the mannose-rich (lanes b, c, d and f) and complex-
glycosylated F508del CFTR isoforms (lanes c–f) were clearly detected by mAbs 570 and
596. The amount of DIDS-insensitive residual chloride secretory activity did not
correlate with signal intensity of the C-band (see Fig. 6, Fig. S2 and Table S2 for ICM and
CFTR protein data on the complete cohort).work all experiments of this study from non-CF (n=8) and F508del
homozygous donors (n=7) yielded interpretable data. To facilitate
the assignment of bands in the autoradiographs, lysed biopsies were
ﬁrst immunoprecipitated with the anti-CFTR antibodies and subse-
quently with polyclonal antibodies raised against the marker protein
sucrase-isomaltase (SI) [22]. These controls helped to assign bands to
CFTR isoforms B and C in the autoradiographs of anti-CFTR IPs
(Fig. 7B). The autoradiographs showed a further diffuse band of higher
mobility than band C but lower than that of band B (Figs. 7 and 8).
Digestion of the IPs with EndoH deglycosylated this band and band B
and shifted their position to that of the deglycosylated CFTR A band
(Fig. 8A). Hence both proteins are core-glycosylated. The cocktail of
our anti-CFTR antibodies utilized for IPs was known to cross-react
with one CFTR-unrelated protein in the molecular weight range
of CFTR isoforms. This non-speciﬁc by-band, however, was sharp
and thus distinct from the diffuse EndoH-sensitive band (see Fig. 8A,
lane b). Hence we concluded that this diffuse band should represent a
further isoform of CFTR that provisonally was named band B* because
of its sensitivity to EndoH. The diffuse band B* has already been seen
before in pulse-chase and immunoprecipitation experiments [31]
when CFTR-transfected baby hamster kidney cells were treated with
the tyrosine kinase inhibitor tyrphostin 47 that enhances CFTR-
mediated transepithelial chloride transport [32]. Since this band B*
has yet only been observed by metabolic labelling, it probably is an
intermediate of post-ER processing of CFTR.Table 1
Ratio of the complex-glycosylated CFTR C-band to the mannose-rich B-band in
immunoblots of lysed rectal biopsies from F508del homozygous CF subjects and a non-
CF subject (control).
Subject no. Density of B-band
(od/mm2)
Density of C-band
(od/mm2)
C/B ratio
Control 1011711 6953689 7
8 1581099 0 0
9 769415 389148 0.5
10 494162 975820 2
11 313578 182694 0.6
12 236680 185384 0.8
13 151372 695356 5
14 62335 629557 10
15 3354 7336 2
16 1253740 0 0
17 598796 0 0
18 23482 931195 40
19 851444 343543 0.4
20 4131 8562 2
Fig. 7. Autoradiographs of metabolically labelled rectal biopsies from non-CF and
F508del (F508d) homozygous CF subjects. (A) Analysis of newly synthesized CFTR.
After ICM and metabolic labelling for 5 h (lanes a, c [22]), 16 h (lane b, [22]) and 15 h
(lanes d–g) the biopsies were lysed and immunoprecipitated with a mixture of anti-
CFTR Abs (see headings above the individual lanes). The IPs were separated by 5% SDS–
PAGE and the dried gels exposed to Biomax MR1 ﬁlms. The complex-glycosylated C-
band of CFTR or of F508del CFTR was visible in lanes a, b, c and g as a broad band and in
lanes d, e and f as a double band. The B-bandwas detected in all lanes. In lanes c, d, e and
f an additionally CFTR-immunoreactive diffuse bandmarked as B*-band was visible, but
not in lanes a, b and g. Lanes a, b and c were reproduced from Fig. 2 of our previous
publication [22] in order to demonstrate that immunoprecipitations with different anti-
CFTR antibodies yielded similar patterns of metabolically labelled CFTR bands in the
autoradiogram. (B) Comparison of the biosynthesis of CFTR and sucrase-isomaltase (SI)
in rectal biopsies from an F508del homozygous individual with CF (lanes c, d) and a
non-CF healthy control (lanes a, b). After ICM andmetabolic labelling, the biopsies were
lysed. The lysates were sequentially immunoprecipitated with mixtures of anti-CFTR
Abs and then of anti-SI Abs (see headings above the individual lanes). SI was chosen as
the reference marker protein because the protocol of metabolic labelling of minute
intestinal biopsies and subsequent IPs had been initially set up for the analysis of SI
[24,25].
Fig. 8. (A) Endo H digestion of metabolically labelled non-CF rectal biopsies. Treatment
with Endo H deglycosylated the mannose-rich bands B and B*, but not the complex-
glycosylated band C (lane b) in biopsies. (B) F508del CFTR analysis by metabolic
labelling or immunoblot of biopsies from the same subject. Metabolic labelling of two
rectal biopsies yielded faint C- and B-bands of F508del CFTR (lane a), whereas the
immunoblot of four biopsies taken six years later revealed a strong B-band, but no C-
band (lane b).
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origin (n=7) revealed no signiﬁcant differences in the band patterns
of autoradiographs of PAGE-separated anti-CFTR IPs (Fig. 7A). The
mature CFTR isoform was present in all investigated F508del
homozygous samples. Thus the complex-glycosylated F508del CFTR
isoform was detected in wild-type amounts in the fraction of newly
synthesized F508del CFTR molecules, but the total amount of the
mature C F508del CFTR glycoform was one to several orders of
magnitude lower than that of complex-glycosylated CFTR in non-CF
rectal mucosa (Fig. 6; see also Fig. 8B for F508del CFTR protein analysis
by immunoblot and metabolic labelling on fresh rectal samples from
the same subject).
4. Discussion
F508del CFTR is the most common mutant amongst all severe
monogenic diseases of Caucasian populations and thus has receivedsubstantial attention to resolve its molecular pathology [3–13,18,19].
Investigations in cell culture models have allowed to classify the
F508del CFTR mutant as a temperature-sensitive folding-trafﬁcking
defect [3–11] that retains residual chloride secretory activity if
delivered to the plasmamembrane [9]. Hence the conﬂicting outcome
of ex vivo studies on human F508del CFTR homozygous distal
intestine [13,18,19] may prima facie be unexpected.
Mall and colleagues [19] measured chloride secretory activities in
rectal biopsies from 12 F508del homozygous individuals. Their ICM
protocol [33] differs in numerous aspects such as buffer constituents,
sequence of secretagogues and mode of recording from the procedure
applied in this study [18,21,29,30]. Cholinergic activation following
IBMX(3-isobutyl-1-methylxanthine)/forskolin led to a maximal appar-
ent chloride secretory response of 3.3 μA/cm2. This value reported by
Mall and colleagues [19] is close to that of the DIDS-insensitive
histamine-evoked chloride secretory response seen in this study. Thus
both protocols unravelled minute residual chloride secretory activity of
F508del CFTR. In other words, the two distinct protocols uncovered – at
least semiquantitatively – similar electrophysiological phenotypes of
F508del CFTR rectal biopsies in the ICM. A major discrepancy between
the outcome of the two studies, however, resides in the F508del CFTR
immunoblot data.
Mall and colleagues [19] cryopreserved the rectal biopsy specimens
after ICM. SubsequentCFTRprotein analysis revealed only the immature
band B isoform for samples from F508del homozygous individuals.
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carriers exhibited both the complex-glycosylated and the core-
glycosylated CFTR isoforms on blots [19]. In contrast, this study
demonstrated complex-glycosylated CFTR in more than 80% of
investigated F508del homozygous and in all non-CF rectal biopsies on
blots.Metabolic labelling of newly synthesized protein [22] revealed the
mature isoform in all analyzed F508del homozygous samples. We took
meticulous care that differences in the immunochemical detection of
CFTR could not account for discordant primary data. Hence the
immunochemical analysis of F508del CFTR was performed to large
extent with the same set of mAbs as used by Mall and colleagues [19].
The major difference between the two studies was the F508del CFTR
protein analysis of either frozen or freshly excised biopsies for the
detection ofmutant CFTR. In ourhands the CFTR-immunoreactive signal
of non-CF biopsies became weaker by freezing and thawing. This
procedure had a stronger impact on the global transcriptome than the
interindividual differences in gene expression (data not shown).
Correspondingly we assume that the cryopreserved material
analyzed by Mall and colleagues [19] had probably lost the labile
F508del CFTR signal below the limit of detection due to the modes of
sampling, storage andhandlingprior to CFTR immunochemical analysis.
However, if the freshly excised sample is rapidly processed with an
optimizedprotocol, theC-bandof F508del CFTR is immunodetectable on
blots. In other words, F508del CFTR is a labile protein in the native
environment in accordance with the data gained in model systems, but
nevertheless complex-glycosylated F508del CFTR exists in most CF
subjects in amounts of 0.1–14% of wild-type CFTR in non-CF subjects
(Fig. 6, Table 1). This fundamental ﬁnding on the fate of F508del CFTR in
F508del homozygous intestinal epithelium substantiates the hope that
correctormolecules [20] suchasVX-809 currently tested in clinical trials
may increase the efﬁcacy of the rescue so that clinically meaningful
amounts of core-glycosylated F508del CFTR are stably converted to the
mature glycoform. The combined administration of a corrector together
with a potentiator of channel activity such as VX-770 [34] could then
ameliorate the basic defect of F508del CFTR.
Our study on the combined ICM and F508del CFTR protein analysis
of the same specimen had the unanticipated outcome that the anion
secretory activity in the ICM was not associated with the pattern of
F508del CFTR glycoforms in the immunoblot. The responses to
carbachol, forskolin/cAMP and histamine in the ICM have been
interpreted to represent chloride secretory responses with CFTR being
the key player [18,21,29,30]. Consistent with this interpretation, the
cumulative value of the responses ΔIsc carbachol, ΔIsc cAMP/forskolin and
ΔIsc histamine has empirically been found to represent the best ICM
parameter to differentiate CF from non-CF [27].
Recent work, however, has demonstrated that a component of the
carbachol-activated current in mouse colon is carried by bicarbonate
through bestrophin Best2 channels [35]. Best2 is expressed at
similarly high levels in human F508del homozygous and non-CF
rectal biopsies [36]. Thus the carbachol-secretory response is probably
composed of more than two currents, i.e. ﬁrst, CFTR-mediated
chloride and bicarbonate secretion, second, non-CFTR-mediated
chloride secretion and third, Best2-mediated bicarbonate secretion.
The secretory response to cAMP/forskolin is also not exclusively
mediated by CFTR in the intestine. An alternative signalling pathway
via the Epac-Rap-PLC-[Ca2+]i cascade stimulates chloride secretion
through a yet unknown chloride channel [37]. This Epac pathway
could reasonably explain the anomalously high response of the
F508del homozygous subject 9 to cAMP/forskolin (see Fig. 4). The
lack of speciﬁcity of the carbachol- and the cAMP/forskolin-evoked
secretory responses was already known when the ICM protocol was
designed. Hence the inhibitor DIDS is added prior to stimulation with
the secretagogue histamine to block almost all chloride conductances
but CFTR [21,29,30]. DIDS is not a speciﬁc inhibitor of CFTR, but the
chosen high concentration of 0.2 mM is still the best tool to virtually
inhibit all chloride conductance in the ICM but CFTR. Alternative drugsto dissect the CFTR-mediated signal from other conductances such as
potentiators like genistein or CFTR inhibitors like inh172 have not
been shown yet to reproducibly work in the ICM so that we adhered to
the original protocol by Veeze et al. [29,30] in this study.
In our study only six of the 20 subjects showed a stronger carbachol-
evoked than histamine-evoked secretory response (Table S2). The
minute net residual chloride secretion in the ICM was DIDS-insensitive
in most CF subjects and thus was ascribed to F508del CFTR activity and
not to any alternative chloride and bicarbonate conductances. In other
words, the variable presence of an alternative ion channel or transporter
could not be the major confounder that caused the experimentally
observed lack of association between the amount of band C F508del
CFTR and chloride secretory activity in F508del homozygous rectal
mucosa. The lack of association more likely reﬂect interindividual
variations of the localization of band C F508del CFTR in the cell.
Detection of complex-glycosylated CFTR indicates that the protein
passed the Golgi apparatus [38] but this does not imply that all mature
CFTR is involved in ICM-detectable activity. Only a fraction of CFTR is
located in the apical membrane where it secretes chloride into the
extracellular space [10]. Wild-type CFTR is endocytosed from and
recycles back to the apical membrane, but F508del CFTR rapidly
disappears from and does not return to the cell surface [10]. Most
CFTR protein resides in the cell interior in a vesicle fraction beneath
the intestinal brush bordermembrane [39], and in the Golgi apparatus
and in the post-Golgi network [10,40] including lysosomal compart-
ments where CFTR has been reported to be involved in vesicular
acidiﬁcation [41]. This broad spatial distribution and the low half-life
of the F508del mutant at the cell surface reasonably explain why the
amounts of mature glycoform and DIDS-insensitive chloride secretion
are only weakly correlated with each other in the F508del condition.
In summary, our study revealed that the majority of investigated
F508del homozygous subjects expressed low amounts of complex-
glycosylated mature F508del CFTR and low residual F508del CFTR-
mediated chloride secretory activity in the rectal mucosa. According
to metabolic labelling F508del CFTR was synthesized and processed at
wild-type levels but then rapidly degraded because the steady state
concentration of complex-glycosylated F508del CFTR was only a few
percent of that of CFTR in the intestine of healthy controls. The
amount of mature F508del CFTR is probably even lower in tissues like
the airways that do not regenerate as fast as the intestinal epithelium.
Consistent with this interpretation, no mature F508del CFTR was
detected in end-stage CF lungs, the major organ afﬂicted in CF.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbadis.2010.08.001.
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